Nerviano Medical Sciences

Discovery and development of new oncology drugs

Slider

Nerviano Medical Sciences

Discovery and development of new oncology drugs

$

SCROLL

$

SCROLL

About us

Nerviano Medical Sciences S.r.l is focused on discovery and clinical development of small molecule NCEs for oncology. The company takes innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients.

Our current pipeline consists of NCEs, which all originate from our well validated oncology drug discovery platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

Nerviano Medical Sciences S.r.l combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharma (manufacturing).

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib. Moreover, we are also developing a proprietary payload platform for generation of novel Antibody-Drug Conjugates (ADCs).

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunies of promising assets for clinical development.

READ OUR STORY

 Research

Our daily commitment

Research is the driving engine of our Company, with a longstanding experience in R&D and a proven track record of being able to perform innovative research and to bring molecules into clinical development up to registration.

Our research addresses different targets in key biological areas and molecular mechanisms that are crucial for onset and progression of diverse cancer types.

Our projects are supported by our scientific platforms, including the Kinase Platform and the ADC platform, that leverage our long standing expertise and technology approaches to generate economy of scale, allowing us to manage a broad project portfolio.

Clinical programs

We are exploiting our core Discovery engine to constantly develop new molecular entities with potential for “first in class” and “best in class”.

Our projects target a broad number of solid tumors and haematological indications, with a focus on biomarker selected patient populations. We are developing projects in house into clinical development in order to accelerate the clinical benefit for our patients.

DISCOVER MORE

 Pipeline

Our pipeline includes outlicensed molecules in advanced clinical stage or already registered, as well as a broad portfolio of molecules at preclinical and clinical stage that are being developed by Nerviano Medical Sciences in different indications.

DISCOVER MORE

Latest News & Events

Nerviano Medical Sciences Appointed Gergely Balint MSc to Accelerate MPS1 Inhibitor Asset Development

01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development and maximize the value of its MPS1 Inhibitor Asset, NMS-01940153E (NMS-153).
(Click the title for the complete article)

Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset – Terrence West, MBA, joins as New Business, Virtual CEO

January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor Asset, NMS-173, and facilitate its expanding and advancing clinical pipeline. Terrence West, MBA, joins as New Business, Virtual CEO.
(Click the title for the complete article)

MPS1 (NMS-01940153E) Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer

MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer

The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). The study findings were reported at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
(Click the title for the complete article)

Latest Events

Latest News

Careers

 Need more information?

Latest Events

Latest News

Careers

 Need more information?

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO